Baylor College of Medicine receives patent for technology exclusively
licensed to Bellicum

August 05, 2015 07:00 AM Eastern Time

HOUSTON--(EON: Enhanced Online News)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) a clinical stage
biopharmaceutical company focused on discovering and developing novel
cellular immunotherapies, today announced that a patent has been issued
to Baylor College of Medicine for methods of inducing apoptosis in cells
that have been infused in patients. Bellicum, which exclusively licensed
the worldwide rights to the technology from Baylor, has incorporated the
invention into BPX-501, its adjunct T cell therapy designed to improve
outcomes in patients undergoing haploidentical hematopoietic stem cell
transplants, now in Phase 1 / 2 clinical studies.

“This important patent extends the proprietary rights of our lead cell
therapy product candidate, BPX-501, until at least 2031”

“This important patent extends the proprietary rights of our lead cell
therapy product candidate, BPX-501, until at least 2031,” commented Tom
Farrell, Bellicum’s President and Chief Executive Officer. “We have
continued to innovate using this and other technologies to create safer
and more effective cell therapies to treat cancers and genetic blood
disorders, strongly positioning Bellicum for success in this rapidly
growing area of medicine.”

The invention is for a method of cell therapy where cells are first
modified to express an inducible caspase 9 protein. The protein, when
triggered with the small molecule compound rimiducid (AP1903), induces
apoptosis and rapid cell death. The cells can be selectively eliminated
when a patient experiences dangerous and life threatening toxicities,
such as Graft versus Host Disease. Baylor was issued U.S. patent number
9,089,520.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing novel cellular immunotherapies for various
forms of cancer, including hematological cancers and solid tumors, as
well as orphan inherited blood disorders. The Company is using its
proprietary Chemical Induction of Dimerization, or CID, technology
platform to engineer and control components of the immune system in real
time. Bellicum is developing next-generation product candidates in some
of the most important areas of cellular immunotherapy, including
hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell
therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.

About Baylor College of Medicine

Baylor College of Medicine (www.bcm.edu)
in Houston is recognized as a premier academic health sciences center
and is known for excellence in education, research and patient care. It
is the only private medical school in the greater southwest and is
ranked 21st among medical schools for research and 11th for primary care
by U.S. News & World Report. Baylor is listed 19th among all
U.S. medical schools for National Institutes of Health funding and
number one in Texas. Located in the Texas Medical Center, Baylor has
affiliations with seven teaching hospitals and jointly owns and operates
CHI St. Luke’s Baylor St. Luke’s Medical Center. Currently, Baylor
trains more than 3,000 medical, graduate, nurse anesthesia, physician
assistant and orthotics students, as well as residents and post-doctoral
fellows. Follow Baylor College of Medicine on Facebook (http://www.facebook.com/BaylorCollegeOfMedicine)
and Twitter (http://twitter.com/BCMHouston).

Forward-Looking Statement

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Bellicum may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should" or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the timing of our clinical trials and of
our research and development activities and our expectations regarding
our other programs. Various factors may cause differences between
Bellicum’s expectations and actual results as discussed in greater
detail in Bellicum’s filings with the Securities and Exchange
Commission, including without limitation our annual report on Form 10-K
for the year ended December 31, 2014. Any forward-looking statements
that Bellicum makes in this press release speak only as of the date of
this press release. Bellicum assumes no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.